MIAMI, Aug. 7, 2014 /PRNewswire/ -- NextSource Biotechnology (NSB) is a leading specialty pharmaceutical manufacturer with a focus on identifying and developing the most viable pipeline of "matured" and "innovative drugs" in today's global healthcare market.

The product name change from Lomustine (CCNU) to GleostineTM represents the company's strategic initiative to re-launch and re-brand its product pipeline of matured and innovative drugs. The new GleostineTM product labeling will be visible in the healthcare market by the fourth quarter of 2014. Lomustine is currently available through all payer organizations nationwide including both commercial and government providers of prescription drug coverage.

GleostineTM is a sole source FDA approved product, which is also accessible through NextSource CARES, NSB's patient assistance program. As a result of the company's extensive market access efforts, the continued use of unregulated compounded products or any other unapproved versions of GleostineTM, will continue to present an unnecessary risk to both healthcare providers and patients. NextSource Biotechnology is committed to providing the highest quality product with a consistent market supply.

"The re-branding of GleostineTM," said Robert DiCrisci, President, CEO of NextSource Biotechnology, "is the first of many product launches to come. As this initiative continues, we will expand our product line to ensure consistent availability to patients with critical medical need."

About NextSource Biotechnology: Established in 2010, NextSource Biotechnology is a leading specialty pharmaceutical manufacturer with a focus on identifying and developing the most viable pipeline of "Matured" and "Innovative drugs" in today's global healthcare market. NextSource partner, CordenPharma Latina is an expert contract manufacturer helping leading pharmaceutical and Biotechnology companies link their requirements for product success with their patients' healthier lives.